Development of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus system

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Nie, Jianhui ^a   Wu, Xiaohong ^a   Ma, Jian ^a   Cao, Shouchun ^a   Huang, Weijin ^a   Liu, Qiang ^a   Li, Xuguang ^b,c   Li, Yuhua ^a   Wang, Youchun ^a  

^a NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^b HEALTH CANADA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RABIES VACCINE;

ANIMAL; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; IN VITRO STUDY; MOUSE; PHYSIOLOGY; PROCEDURES; RABIES VIRUS; REPRODUCIBILITY; SERODIAGNOSIS; VIRUS LOAD;

ANIMALS; HEK293 CELLS; HUMANS; IN VITRO TECHNIQUES; MICE; NEUTRALIZATION TESTS; RABIES VACCINES; RABIES VIRUS; REPRODUCIBILITY OF RESULTS; VIRAL LOAD;

EID: 85013471843     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep42769     Document Type: Article

References (48)

1. Fooks, A. R. et al. Current status of rabies and prospects for elimination. Lancet 384, 1389-1399, doi: 10.1016/S0140-6736(13)62707-5 (2014).
2. Hampson, K. et al. Estimating the global burden of endemic canine rabies. PLoS neglected tropical diseases 9, e0003709, doi: 10.1371/ journal.pntd.0003709 (2015).
3. Meslin, F. X. & Briggs, D. J. Eliminating canine rabies, the principal source of human infection: what will it take? Antiviral research 98, 291-296, doi: 10.1016/j.antiviral.2013.03.011 (2013).
4. World Health, O. WHO Expert Consultation on Rabies. Second report. World Health Organization technical report series, 1-139, back cover (2013).
5. Publication, W. H. O. Rabies vaccines: WHO position paper-recommendations. Vaccine 28, 7140-7142, doi: 10.1016/j. vaccine.2010.08.082 (2010).
6. Hooper, D. C. et al. Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system. Journal of virology 72, 3711-3719 (1998).
7. Rabies vaccines. WHO position paper. Wkly Epidemiol Rec 85, 309-320 (2010).
8. Smith, J. S., Yager, P. A. & Baer, G. M. A rapid reproducible test for determining rabies neutralizing antibody. Bulletin of the World Health Organization 48, 535-541 (1973).
9. Cliquet, F., Aubert, M. & Sagne, L. Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. Journal of immunological methods 212, 79-87 (1998).
10. Welch, R. J., Anderson, B. L. & Litwin, C. M. An evaluation of two commercially available ELISAs and one in-house reference laboratory ELISA for the determination of human anti-rabies virus antibodies. J Med Microbiol 58, 806-810, doi: 10.1099/ jmm.0.006064-0 (2009).
11. Chosewood, L. C. & Wilson, D. E., Centers for Disease Control and Prevention (U.S.) & National Institutes of Health (U.S.). Biosafety in microbiological and biomedical laboratories. 5th edn, (U.S. Dept. of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention For sale by the Supt. of Docs., U.S. G.P.O., 2009).
12. Hanlon, C. A., Niezgoda, M. & Rupprecht, C. E. Postexposure prophylaxis for prevention of rabies in dogs. Am J Vet Res 63, 1096-1100 (2002).
13. Moore, S. M. & Hanlon, C. A. Rabies-specific antibodies: measuring surrogates of protection against a fatal disease. PLoS neglected tropical diseases 4, e595, doi: 10.1371/journal.pntd.0000595 (2010).
14. Franka, R. et al. Rabies virus pathogenesis in relationship to intervention with inactivated and attenuated rabies vaccines. Vaccine 27, 7149-7155, doi: 10.1016/j.vaccine.2009.09.034 (2009).
15. Rosseels, V. et al. A non-invasive intranasal inoculation technique using isoflurane anesthesia to infect the brain of mice with rabies virus. Journal of virological methods 173, 127-136, doi: 10.1016/j.jviromet.2011.01.019 (2011).
16. Long, J., Wright, E., Molesti, E., Temperton, N. & Barclay, W. Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. F1000Research 4, 30, doi: 10.12688/f1000research.6085.2 (2015).
17. Corti, D. et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proceedings of the National Academy of Sciences of the United States of America 112, 10473-10478, doi: 10.1073/pnas.1510199112 (2015).
18. Lagging, L. M., Meyer, K., Owens, R. J. & Ray, R. Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus. Journal of virology 72, 3539-3546 (1998).
19. Mallajosyula, V. V. et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proceedings of the National Academy of Sciences of the United States of America 111, E2514-2523, doi: 10.1073/pnas.1402766111 (2014).
20. Kobayashi, K., Kato, S., Inoue, K., Takada, M. & Kobayashi, K. Altering Entry Site Preference of Lentiviral Vectors into Neuronal Cells by Pseudotyping with Envelope Glycoproteins. Methods in molecular biology 1382, 175-186, doi: 10.1007/978-1-4939-3271-9-12 (2016).
21. Azzouz, M. et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429, 413-417, doi: 10.1038/nature02544 (2004).
22. Mentis, G. Z. et al. Transduction of motor neurons and muscle fibers by intramuscular injection of HIV-1-based vectors pseudotyped with select rabies virus glycoproteins. Journal of neuroscience methods 157, 208-217, doi: 10.1016/j.jneumeth.2006.04.011 (2006).
23. Wright, E. et al. A robust lentiviral pseudotype neutralisation assay for in-field serosurveillance of rabies and lyssaviruses in Africa. Vaccine 27, 7178-7186, doi: 10.1016/j.vaccine.2009.09.024 (2009).
24. Wright, E. et al. Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison. The Journal of general virology 89, 2204-2213, doi: 10.1099/vir.0.2008/000349-0 (2008).
25. Mochizuki, H., Schwartz, J. P., Tanaka, K., Brady, R. O. & Reiser, J. High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. Journal of virology 72, 8873-8883 (1998).
26. Federici, T. et al. Comparative analysis of HIV-1-based lentiviral vectors bearing lyssavirus glycoproteins for neuronal gene transfer. Genet Vaccines Ther 7, 1, doi: 10.1186/1479-0556-7-1 (2009).
27. Carpentier, D. C. et al. Enhanced pseudotyping efficiency of HIV-1 lentiviral vectors by a rabies/vesicular stomatitis virus chimeric envelope glycoprotein. Gene therapy 19, 761-774, doi: 10.1038/gt.2011.124 (2012).
28. Nie, J. et al. Optimization and proficiency testing of a pseudovirus-based assay for detection of HIV-1 neutralizing antibody in China. Journal of virological methods 185, 267-275, doi: 10.1016/j.jviromet.2012.07.011 (2012).
29. Ozaki, D. A. et al. International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials. PloS one 7, e30963, doi: 10.1371/journal.pone.0030963 (2012).
30. Todd, C. A. et al. Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. Journal of immunological methods 375, 57-67, doi: 10.1016/j.jim.2011.09.007 (2012).
31. Bland, J. M. & Altman, D. G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1, 307-310 (1986).
32. Dietzschold, B., Li, J., Faber, M. & Schnell, M. Concepts in the pathogenesis of rabies. Future virology 3, 481-490, doi: 10.2217/17460794.3.5.481 (2008).
33. Swirski, F. K. et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325, 612-616, doi: 10.1126/science.1175202 (2009).
34. Ray, N. B., Ewalt, L. C. & Lodmell, D. L. Rabies virus replication in primary murine bone marrow macrophages and in human and murine macrophage-like cell lines: implications for viral persistence. Journal of virology 69, 764-772 (1995).
35. Li, J., McGettigan, J. P., Faber, M., Schnell, M. J. & Dietzschold, B. Infection of monocytes or immature dendritic cells (DCs) with an attenuated rabies virus results in DC maturation and a strong activation of the NFkappaB signaling pathway. Vaccine 26, 419-426, doi: 10.1016/j.vaccine.2007.10.072 (2008).
36. Nie, J., Liu, Y., Huang, W. & Wang, Y. Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus. Viruses 8, 107, doi: 10.3390/v8040107 (2016).
37. Johnson, K. M. et al. Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. Journal of virology 83, 2067-2074, doi: 10.1128/JVI.02190-08 (2009).
38. Niwa, H., Yamamura, K. & Miyazaki, J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108, 193-199 (1991).
39. Wei, X. et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrobial agents and chemotherapy 46, 1896-1905 (2002).
40. Li, M. et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. Journal of virology 79, 10108-10125, doi: 10.1128/JVI.79.16.10108- 10125.2005 (2005).
41. Matumoto, M. A note on some points of calculation method of LD50 by Reed and Muench. The Japanese journal of experimental medicine 20, 175-179 (1949).
42. Chong, H. et al. Genetic and neutralization properties of HIV-1 env clones from subtype B/BC/AE infections in China. Journal of acquired immune deficiency syndromes 47, 535-543, doi: 10.1097/QAI.0b013e3181663967 (2008).
43. WHO Expert Committee on Rabies. World Health Organization technical report series 824, 1-84 (1992).
44. Bourhy H. & Sureau P. Laboratory methods for rabies diagnosis 191-193. (Paris: Institut Pasteur, 1990).
45. Liu, Q. et al. Bioluminescent imaging of vaccinia virus infection in immunocompetent and immunodeficient rats as a model for human smallpox. Scientific reports 5, 11397, doi: 10.1038/srep11397 (2015).
46. Zaitseva, M. et al. Application of bioluminescence imaging to the prediction of lethality in vaccinia virus-infected mice. Journal of virology 83, 10437-10447, doi: 10.1128/JVI.01296-09 (2009).
47. Luker, K. E. & Luker, G. D. Applications of bioluminescence imaging to antiviral research and therapy: multiple luciferase enzymes and quantitation. Antiviral research 78, 179-187, doi: 10.1016/j.antiviral.2008.01.158 (2008).
48. Xu, S. et al. Comparative evaluation of the COBAS AmpliPrep/COBAS TaqMan HIV type 1 test (CAP/CTM) and VERSANT HIV type 1 RNA 3.0 assay (bDNA) for quantifying HIV type 1 viral loads in China. AIDS Res Hum Retroviruses 24, 1365-1373, doi: 10.1089/aid.2008.0005 (2008).